


Clinical Pearls for the Primary Eye Care Practice Practical Solutions For Complex Cases

Professional Education 2025
March 23, 2025 Columbus, OH

Michael DePaolis, OD, FFAO
Flaum Eye Institute - UR Medicine
mgadep@gmail.com
michael_depaolis@urmc.rochester.edu



1

Michael DePaolis, OD, FFAO
Financial disclosure statement

- Associate Professor of Clinical Ophthalmology
Flaum Eye Institute @ UR Medicine
- Optometric Editor, Primary Care Optometry News
- No financial disclosures



2

Clinical Pearls for the Primary Eye Care Practice

*Clinical pearls are best defined as **small bits** of free standing, **clinically relevant** information based on **experience or observation**. They are part of the vast domain of **experience-based medicine**, and can be helpful in dealing with **clinical problems** for which **controlled data do not exist**.*

Lorin, etal Med Teach 2008.

3

Clinical Pearls For The Primary Eye Care Practice

Clinical Case - 56 yof

Ocular history: c/o blurred vision with eyeglasses. Corneal dystrophy. Brother with PKP and graft rejection. Wants to avoid surgery. Muro gtt prn - limited relief.


VA cc OD 20/100 & OS 20/80.

Biomicroscopy - Mild ABMD and Fuch's endothelial dystrophy OU.

Impression: ABMD OU, Fuch's corneal dystrophy OU.

Plan:

- Biofinity 8.7 14.5
-300 -125 x 70 = 20/30
-350 -150 x 110 = 20/25
- Clear care qhs / replace q 1 month
- Muro ung OU qhs.



4

Clinical Pearls For The Primary Eye Care Practice

Clinical Case 56 yof - 2 year f/u visit

Ocular history: 'vision in right eye a little blurry.' Wearing soft lenses qd x 12+ hours. Clear care qhs. Replace q 1 mth. Muro ung OU qhs.


VA cc OD 20/60 & OS 20/30.

Biomicroscopy - ABMD stable OU. Progressive Fuch's endothelial dystrophy.

Impression: ABMD OU, Fuch's corneal dystrophy OD > OS.

Plan:

- DSAEK vs DMEK consult.
- Continue with contact lenses in interim.



5

Clinical Pearls For The Primary Eye Care Practice

Clinical Pearls

Fuch's Dystrophy

- Female > male. Symptomatic 6th decade. Autosomal dominant
- Genetics + environment -> ECM deposition -> apoptosis
- Repeating trinucleotide on **TCF4 gene 96% positive predictor** (Baratz ARVO 2012)

Diagnosis


- Symptoms
- Biomicroscopy, Speculars, & Pachymetry

Repp, etal Oph 2013

- Central:Peripheral corneal thickness ratio (scan slit pachymetry)
- Advanced = **1.03** Mild-moderate = 0.95 Controls = **0.87**

Patel Cornea 2021

- Scheimpflug tomography



6

Clinical Pearls For The Primary Eye Care Practice

Clinical Pearls

Muro 5% ung vs FreshKote qhs?

Muro 12g - 5% NaCl hyperosmotic

FreshKote - PVA:Povidone creating high osmotic gradient

DSAEK vs DMEK?

Majmudar, Oc Surg News 2014

DMEK quicker recovery, less rejection, better BCVA, & less + Rx shift

Weisenthal, etal Am J Oph 2022

N = 128 eyes DMEK vs DSAEK with 2 yr follow-up

DMEK faster recovery, but vision similar @ 2 yr

DMEK vs UT-DSAEK?

Dunker, etal Ophth 2020

N = 54 pseudophakes with Fuch's randomized to DMEK vs UT-DSAEK

BCVA 20/25+ DMEK 66% vs UT-DSAEK 33%. Less + Rx shift in DMEK.

Do we even need donor tissue... DSO?

Garcerant, etal Curr Op Oph 2019

- Clearing in 63-100% cases with DSO across all series

- Rho-kinase inhibitor (riposudil) adjunct critical

Din, etal Cornea 2022

- Ovid, Embase, & Cochrane database search

- DSO success - 4 mm rhexis, good peripheral ECD, thinner central pachymetry, and adjunct Rho-kinase inhibitor

7

Clinical Pearls For The Primary Eye Care Practice

Clinical Case - 63 yof

Ocular History: Successful monovision soft CL wear.
C/O dryness, blurred vision, and contact lens intolerance.
"I think my dryness is due to my medications"

Contact Lens History: Biofinity Toric SCL. ReNu qhs. Rep q2 mth .

Systemic History: HTN, hypo-T, **Non-smoker small cell lung CA.**

Medications: Amlodipine, levothyroxine, & **Tarceva.** NKDA.

Exam: VA OD cc 20/60 & OS cc 20/50
Pupils, motilities, & CVF's normal OU
IOP's 14 OU
DFE: Normal disc, macula, vessels, periphery OU

8

Clinical Pearls For The Primary Eye Care Practice

Clinical Case - 63 yof

Refraction: OD - 1.25-0.75x180 / +2.25 = 20/25
OS - 2.00-0.50x170 / +2.25 = 20/40


Biomicroscopy: Mild MGD, mild conjunctival injection, coalesced SPK, & TBUT 3-5 sec. Grade 1 NS OU.

Tear Osmolarity 308 mOsm/L OD & 319 mOsm/L

Impression: Tear deficient & evaporative dry eye (likely iatrogenic)

Plan:

- Environment, hydration, & omega 3's
- Hot compress qd x 5 minutes
- Systane Hydration PF qid,
- Lotemax gel bid,
- Precision 1 toric OD / no lens OS



9

Clinical Pearls For The Primary Eye Care Practice

Clinical Case - 63 yof

2 week follow-up:


Ocular History: Compliant with all treatments. Right eye feels much better and is much clearer. Left eye still symptomatic.

VA: OD scl 20/25 (D) & OS sc J3 (N)

Biomicroscopy: Mild MGD OU, trace injection OS > OD, trace SPK OD & coalesced SPK OS, AC d&q, iris normal, grade 1 NS

Plan:

- Hydration and omega 3s
- Hot compress qd x 5 minutes
- Systane Hydration PF qid
- Precision 1 toric OD & Precision 1 +050 OS



10

Clinical Pearls For The Primary Eye Care Practice

Clinical Pearls

Just what is Tarceva?

- Erlotinib is an EGFR inhibitor approved for pancreatic cancer and metastatic non-smoker small cell lung cancer

Tyrosine Kinase Inhibitors

- Erlotinib (Tarceva)
- Gefitinib (Iressa)
- Afinitinib (Gilotrif)
- Osimertinib (Tagrisso)

Monoclonal Antibodies

- Cetuximab (Erbbitux)
- Panitumumab (Vectibix)
- Necitumumab (Portrazza)

EGFR Side Effects

- Common - Xerosis, alopecia, paronychia, mucositis
- Serious - SJS-TEN, Hepatotoxicity, Interstitial Lung Disease

11

Clinical Pearls For The Primary Eye Care Practice

Clinical Pearls

Ocular Sequelae of Tarceva

- Borkar, etal Sup Care Cancer 2013
- Dry Eye
 - Blepharitis and trichiasis
 - Corneal abrasions and sterile melts
- Sun, etal J Clin Pharm (2018)
 - Ocular side effects **dose dependent**
 - Erlotinib > 150mg per day



What are reasonable **adjunct** treatments?

- Punctal plugs
- Cyclosporin, Lifitigrast, Loteprednol, Varenicline, Perfluorohexyloctane
- Amniotic membrane
- Bandage Contact Lenses (Inamoto, etal Biol Blood Marrow Transplant 2015)

12

Clinical Pearls For The Primary Eye Care Practice

Clinical Case - 35 yof

Ocular History: Dx of 'forme fruste' keratoconus 3 months prior. Intolerant to GPCL. Resumed SCL wear. C/O blurry and cloudy VA. Eyes burn & tear after lens removal.

Contact Lens History: Acuvue Oasys OU. OptiFree Replenish qhs. No rub, no rinse. Replaces q 2-3 mths.

Systemic History: Excellent. No medications. NKDA.

Exam: VA OD cc 20/30 & OS cc 20/70 (spectacles)
Pupils, motilities, and CVF's normal OU
IOP's: 12mm Hg OU
DFE: Normal disc, macula, vasculature, periphery OU

13

Clinical Pearls For The Primary Eye Care Practice


Clinical Case - 35 yof

Refraction: OD -4.25-0.75 x 100 = 20/20-
OS -5.00-0.50 x 50 = 20/25

Simulated Keratometry: OD 43.78 x 44.35 @ 48
OS 43.70 x 44.48 @ 7

Keratoconus Indices:

Negative OD
Negative OS



14

Clinical Pearls For The Primary Eye Care Practice

Clinical Case - 35 yof

Biomicroscopy:

Moderate MGD OU
Mild conjunctival injection OU
Superior limbal haze OU

Negative wetting whorl epitheliopathy
AC d&q OU
Iris normal OU
Lens clear OU

Pachymetry:
545u OD
538u OS



15

Clinical Pearls For The Primary Eye Care Practice

Clinical Case - 35 yof

Impression: MGD evaporative dry eye OU
CL related limbal stem cell deficiency OU

Plan:

- Discontinue contact lenses
- Lotemax gel OU qid x2 wk, bid x2 wk
- Bruder Mask OU qd
- Blink PF OU qid
- 1000 mg fish oil qd (EPA/DHA)
- 500 mg Vitamin C bid
- F/U 1 mth

1 month f/u

CC: eyes feel much better. VA stable. No burning or tearing.

VA OD cc 20/20 OS cc 20/25

Biomicroscopy: Fading stromal haze OU. Improved ocular wetting OU.

Plan:

- Continue Bruder mask qhs, omega 3s, and Blink PF qid
- Eventual refit Alcon Dailies Total 1 8.5 -4.50 OD & -4.75 OS

16


Clinical Pearls For The Primary Care Practice

What is Limbal Stem Cell Deficiency (LSCD) ?

- Corneal epithelial stem cells are within the Palisades of Vogt
- Stem cells progressively differentiate and migrate centrally (transiently amplifying-> migratory basal -> wing -> surface)
- Corneal "homeostasis" Landage, et al Inv Oph & Vis Sci 2003.
- Limbal stem cell function is modulated by developmental, hormonal, neuronal, vascular and inflammatory factors

LSCD caused by

- Congenital Diseases
- Infection
- Inflammation
- Immune disorders
- Trauma (contact lens)
- Chemical, thermal, radiation burns



17

Clinical Pearls For The Primary Care Practice

Clinical Pearls

Contact Lens induced LSCD

- 2.5% of all contact lens wearers (Martin Clin Exp Optom 2007)
- Bilateral - most often superior limbus with whorl epitheliopathy
- Conjunctival goblet cells on cornea via impression cytology

Termote, et al Can J Oph 2017

- N = 27 eyes with CL related LSCD
- All soft lenses / 75% Si-Hy lenses
- Mean wear time 18.1 years
- PF topical steroids & PF AT gtt

Kim, et al Ophth 2014

- N = 22 eyes with CL related LSCD
- 18% resolved with CL discontinuation and PF OTC AT's
- 82% required topical steroids, topical cyclosporin, topical vitamin A, oral doxycycline, punctal plugs



18

Clinical Pearls For The Primary Eye Care Practice

How is LSCD best managed ?

Partial LSCD

- Lubrication
- Anti-inflammatory agents (corticosteroid, cyclosporin, lifitegrast)
- Vitamin A. ung – Optase HyloNight PF (250 IU/g Retinol Palmitate)
- Amniotic Membrane
 - Cryopreserved vs Dehydrated
- Autologous serum or Platelet Rich Plasma
 - Hussain, etal Cornea (2014) "Reasonable in severe disease"
- Topical Interferon a-2b and ATRA
 - Tan, etal B J Opth 2016

Total LSCD Fernandez, etal BMJ Open Opth 2018

- direct autologous limbal (AULT) – risk to contralateral eye ?
- direct allogenic limbal (ALLT) – donor and immunosuppressive ?
- oral mucosal epithelial transplantation – 50-70% successful
- cultured AULT and ALLT – 75-84% successful

Lee, etal JAMA 2020

- Meta-analysis of 40 studies – 2202 eyes
- Improved ocular surface: AULT = cAULT > cALLT > ALLT
- Improved vision: AULT > cAULT = ALLT > cALLT

19

Clinical Pearls For The Primary Eye Care Practice

Clinical Case - 44 yof

Ocular History:

Referred by corneal specialist
 Previously wore soft contact lenses, but d/c due to dryness
 Previous OTC: Refresh, Systane, & TheraTears
 Previous Rx: Pred Forte & Alrex
 Current eye gtt: Pataday ou bid, Restasis ou bid, fish oil daily

Cc: 'I get **eye hemorrhages monthly**. I'd like to get back into wearing contact lenses if possible.'

Systemic History: +Anxiety. (-) Thyroid. (-) Rheumatology.
 (-) hematology work-up.

Medications: Fluoxetine qd, Fish oil qd.

20

Clinical Pearls For The Primary Eye Care Practice

Clinical Case - 44 yof

VA: OD Rx 20/20- & OS Rx 20/20.


Externals: (+) malar flush

Biomicroscopy:

Grade 3 MGD OU
 Grade 2 conjunctivochalsis OU
 Grade 1 conjunctival LG stain OU
 Cornea clear with TBUT 8-10 sec OU
 Tear prism <0.5mm OU

Impression:

- MGD
- Combined DED
- Rosacea (ocular)
- Subconjunctival hemorrhage (Menstrual related ?)



21

Clinical Pearls For The Primary Eye Care Practice

Clinical Case - 44 yof

Plan:

- Spoke with ob-gyn – r/o causes for menorrhagia
- Doxycycline 50 mg bid
- Bruder Mask OU bid
- Nordic Naturals ProOmega – 2 softgels po qd
- Lotemax gel OU bid
- Pataday OU qam
- Restasis OU bid

1-month follow-up

Doing much better symptomatically
 Biomicroscopy: improved MGD, LG staining, & TBUT.
 Conjunctivochalsis persists.

Plan:

- Discontinue Lotemax gel
- Continue all other treatments
- 1-month follow-up

22

Clinical Pearls For The Primary Eye Care Practice

Clinical Case - 44 yof

2 month follow-up

CC: 'doing great, no hemorrhages.'

VA: OD Rx 20/20 & OS Rx 20/20.

Biomicroscopy:

Gr 1 MGD OU
 Gr 1 conjunctivochalsis w/o lissamine green staining OU
 Cornea clear with TBUT ~ 10 seconds OU

Plan:

- Continue hot compress OU qd
- Continue Restasis OU bid & Pataday OU prn
- Continue ProOmega qd
- Doxycycline 50 mg qd x 1 mth, then discontinue
- BioTrue Daily Disposable

23

Clinical Pearls For The Primary Eye Care Practice

Clinical Pearls

Is conjunctivochalsis the "demon in the closet?"

Acera, etal Invest Ophth Vis Sci 2013

- N = 12 eyes conjunctival resection conjunctivochalsis
- Less epithelial defects, epiphora, and symptoms
- Improved matrix metalloproteinase 9 levels

Yamamoto, etal Eye Cont Len 2015 epub

- N = 362 pts with subconjunctival hemorrhage (SCH)
 - Conjunctivochalsis + visual demands = 3+ SCH
- N = 38 pts conjunctivochalsis (CCH) surgery for SCH
 - 80+% no SCH recurrence after surgery

Is low dose corticosteroid a reasonable adjunct?

- Lotemax SM (0.38% loteprednol)
 - Pflugfelder AJO 2004 – loteprednol safe & effective for inflammatory DE
- Dextenza (0.4mg dexamethasone punctal plug)
 - FDA approval for post-op adjunct time release over 30 days
- Florex (0.1% fluorometholone acetate, Harrow)
- Pinto-Fraga AJO 2016 – FML improves dry eye and buffers flares
- Eysuvis (0.25% loteprednol)
- Korenfeld, etal Cornea 2021 – Safety / efficacy in managing dry eye

24

Clinical Pearls For The Primary Eye Care Practice

Clinical Pearls

Is a low dose oral contraceptive acceptable in recurrent menstrual cycle subconjunctival hemorrhage?

Dua, etal Ophth Plast Reconstr Surg 2014

- Case of 'vicarious orbital menstruation' responded favorably to **oral contraceptives**

What else to keep in mind?

- Anti-coagulative medications
- Clotting conditions
 - Hemophilia
 - von Willebrand disease
- Platelet disorders
 - Thrombocytopenia purpura
- Blood malignancies
 - Leukemia

25

Clinical Pearls For The Primary Eye Care Practice

Clinical Pearls

- Meibomian Gland Thermal Therapy
 - LipiFlow (J&J) Thermal Pulse Tx (J&J LipiFlow)
 - Blackie, etal Clin Oph 2016
 - LipiFlow superior to HC - 86% maintain **up to 1 year**
 - I-Lux (Alcon) – comparable to LipiFlow @ 1mth Merchea AAO 2019
 - Tear Care (Sight Sciences) – Olympia Trial clinicaltrials.gov
 - Badawi Clin Ther 2019 – TearCare superior to HC. **Retx @ 6mth**
 - IPL + MGX – effective in refractory MGD Arita, etal Oc Surf 2019
- Immunomodulation
 - IMPACT Study Stonecipher, etal Clin Oph 2016
 - Restasis bid x 6 month - OSDI, staining, TBUT, & **visual scores**
 - OPUS-1 Sheppard, etal Oph 2014
 - Xiidra bid – improved SPK & LG stain (**day 14**) & symptoms (**day 84**)
 - OTX-1 Study Tauber, etal Clin Oph 2018
 - Cequa - improvements in corneal & conjunctival stain, & Schirmer's
 - ESSENCE-2 Study Wirta, etal Cornea 2024
 - Vevye – improvements in corneal staining, Schirmer's, & symptoms

26

Clinical Pearls For The Primary Eye Care Practice

Clinical Case – 62 yof

Ocular History: Reis-Buckler's corneal dystrophy.
PTK OD 2006 and OS 2007 with **repeat OU** in 2014.
c/o intermittent irritation, photophobia, and blurred VA.
Systemic History: Excellent. No medications. NKDA.
Family History: Mother and Daughter with Reis-Buckler's.

VA OD cc 20/70 & OS cc 20/80 (spectacles)
Pupils, motilities, and CVF normal OU
IOP's: 12mm Hg OU
DFE: Normal disc, macula, vasculature, periphery OU

OD +1.00-1.00 x 25 = 20/70
OS +1.00-1.00 x 165 = 20/80-

27

Clinical Pearls For The Primary Eye Care Practice

Clinical Case – 62 yof

Biomicroscopy: Recurrent Reis-Buckler's Corneal Dystrophy OU


Contact Lens Tx:

Biofinity Toric 8.6
OD +1.25-0.75x40 = 20/40
OS +0.50-0.75x140 = 20/50-

Clear Care qhs
Monthly replacement
Polysporin ung OU qhs prn

Pachymetry 653u OD and 743u OS.

Next step??



28

Clinical Pearls For The Primary Eye Care Practice

Clinical Case – 62 yof

Biomicroscopy: Recurrent Reis-Buckler's Corneal Dystrophy OU

PTK OU 2023

BCVA OD 20/50 & OS 20/50+


Biomicroscopy:

Reis-Buckler's Corneal Dystrophy with improved corneal clarity OU.

2+ Nuclear Sclerotic Cataract OU.

Next step??

Phaco + IOL OU vs PKP followed by CE



29

Clinical Pearls For The Primary Eye Care Practice

Clinical Pearls

What is Reis-Buckler's Dystrophy and prognosis?

- Autosomal Dominant with symptoms onset 2nd decade of life
- Early symptoms of RCE and foreign body
- Later symptoms of photophobia and blur
- Changes primarily at **Bowman's and anterior stroma** ??

Qui, etal BMC Ophth 2016

- RBCD linked to mutation of TGFBI gene
- TGFBI-protein greatest in stroma
- Confocal microscopy, AS-OCT, and histology – **deep stroma!**




image courtesy of aao.org

30

Clinical Pearls For The Primary Eye Care Practice

Clinical Pearls PTK or DALK or PKP?

Vinciguerra, etal J Ref Surg 2018

- N = 14 RBCD eyes treated with sequential customized PTK
- m BCVA improved from 20/50 to 20/25
- N = 2 eyes required repeat surgery over 5 yr follow-up

Qui, etal BMC Ophth 2016

- N = 4 RBCD eyes treated with **DALK** w/o recurrence to date
- Reddy, etal Cornea 2015
- N = 109 **PKP** eyes and 21 **DALK** eyes over 1 year
- **DALK** less endothelial graft rejection & glaucoma

Chan, etal Can J Oph 2018

- N = 1104 consecutive corneal transplants @ KEI over 3 years
- **80% lamellar surgeries**
- **DALK** increasing and **PKP** decreasing

31

Clinical Pearls For The Primary Eye Care Practice

Case study – 40 yof

Ocular History

- c/o dryness OU and foreign body sensation OS x 3 years.
- chalazion removal LUL 3 years ago with symptoms ever since.
- LUL swells and droops. Recent neuro-eye consult negative.
- Xiidra bid, TheraTears prn. Hot compress. Omega 3's daily.
- Systemic History: Negative. No meds.

Exam:

UCVA: 20/20- OD & 20/20 OS.

Externals: Pupils, motilities, and CVF normal OU.
IOP 19 OD and 19 OS.

32

Clinical Pearls For The Primary Eye Care Practice

Case study – 40 yof

Biomicroscopy:

- Trace MG inspissation OU.
- No tarsal foreign body on LUL eversion.
- Conjunctiva clear with weak tear prism.
- Trace inferior SPK OU. TBUT 3-5 seconds OU. No ABMD.

Diagnosis: Bilateral Dry Eyes

Plan:

- Continue Xiidra OU bid.
- Continue TheraTears OU bid.
- Bruder Mask daily x 5 minutes.
- GNC TS Fish Oil Mini bid.
- Lotemax gel OS qhs
- 1-month follow-up



33

Clinical Pearls For The Primary Eye Care Practice

Case study – 40 yof

1- month follow-up:

- Symptoms improved with Lotemax gel, but now worse again.
- Compliant with all other tx.

Biomicroscopy:

- Unchanged.
- Tarsal fissure LUL.
- No staining or fb track

Impression: Bilateral Dry eyes
Tarsal Fissure LUL

Plan:

- Continue all dry eye tx
- Totals Dailies 1 8.5 -0.25 OS.
- Schedule oculoplastics consult.



34

Clinical Pearls For The Primary Eye Care Practice

Clinical Pearls

- Tarsal conjunctival keloids rare
 - D'Hermies, etal J Fr Oph 2003
 - Lim & Son SpringerPlus 2016
- Management
 - Bandage Contact Lens
 - Ung qhs
 - Triamcinolone injection
 - Surgical Revision
 - amniotic membrane graft
 - mitomycin C
- Other sources of tarsal fibrosis
 - Papillary conjunctivitis
 - Vernal conjunctivitis
 - Conjunctival lithiasis
 - Pyogenic granuloma
 - Cicatricial Ocular Pemphigoid

35

Clinical Pearls For The Primary Eye Care Practice

Thank you for attending!



Michael DePaolis, OD, FAAO
Flaum Eye Institute / URMedicine
mgadep@gmail.com
michael_depaolis@urmc.rochester.edu

36